Phibro Animal Health Corporation (PAHC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Phibro Animal Health Corporation (PAHC) Healthcare & Pipeline Overview

Phibro Animal Health Corporation (PAHC) is a global diversified animal health and mineral nutrition company, providing solutions for livestock producers. With a focus on innovation and a wide range of products, PAHC serves key markets including the United States, Latin America, and Asia Pacific, maintaining a competitive edge through its integrated approach.

What Is the Investment Thesis for PAHC?

Phibro Animal Health Corporation presents a compelling investment case based on its diversified product portfolio and global reach in the animal health market. With a P/E ratio of 13.1 and a profit margin of 6.3%, the company demonstrates stable profitability. Key value drivers include the increasing demand for animal protein and the growing awareness of animal health and nutrition. Growth catalysts include expansion into emerging markets and the development of innovative products. However, potential risks include regulatory changes and competition from generic products. The company's dividend yield of 1.20% offers a modest return for investors.

Based on FMP financials and quantitative analysis

PAHC Key Highlights

• Market Cap of $1.34B reflects Phibro Animal Health Corporation's significant presence in the animal health market.
• P/E Ratio of 13.1 indicates a reasonable valuation compared to its earnings.
• Gross Margin of 32.5% demonstrates the company's ability to manage production costs effectively.
• Dividend Yield of 1.20% provides a steady income stream for investors.
• Beta of 0.69 suggests lower volatility compared to the overall market, making it a relatively stable investment.

Who Are PAHC's Competitors?

PAHC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PAHC's Key Strengths?

• Diversified product portfolio.
• Global presence in key markets.
• Established relationships with customers.
• Strong focus on innovation.

What Are PAHC's Weaknesses?

• Dependence on regulatory approvals.
• Exposure to commodity price fluctuations.
• Competition from generic products.
• Limited brand recognition compared to larger players.

What Could Drive PAHC Stock Higher?

• Potential regulatory approvals for new animal health products.
• Expansion into emerging markets, particularly in Asia Pacific and Latin America.
• Development and launch of innovative animal health solutions.
• Strategic acquisitions to expand product portfolio and geographic reach.

What Are the Key Risks for PAHC?

• Regulatory changes affecting the animal health industry.
• Disease outbreaks impacting livestock populations.
• Economic downturns reducing demand for animal protein.
• Competition from generic products.
• Fluctuations in commodity prices affecting production costs.

What Are the Growth Opportunities for PAHC?

• Expansion in Emerging Markets: Phibro has the opportunity to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where the demand for animal protein is growing rapidly. These regions present significant growth potential due to increasing populations and rising incomes. By establishing local sales offices and distribution networks, Phibro can capitalize on this demand and increase its market share. This expansion could contribute significantly to revenue growth over the next 3-5 years.
• Development of Innovative Products: Investing in research and development to create innovative animal health products, such as vaccines and nutritional supplements, can drive growth. The market for specialized animal health products is expanding as livestock producers seek to improve animal health and productivity. By developing and launching new products, Phibro can differentiate itself from competitors and capture a larger share of the market. This strategy could lead to a 10-15% increase in revenue within the next 2-3 years.
• Strategic Acquisitions: Phibro can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary products or technologies can enhance Phibro's competitive position and accelerate growth. For example, acquiring a company specializing in aquaculture health products could enable Phibro to enter a new market segment. Strategic acquisitions could contribute to a 5-10% increase in revenue within the next year.
• Strengthening Distribution Channels: Enhancing its distribution channels, including partnerships with commercial animal feed manufacturers, wholesalers, and distributors, can improve Phibro's market access and sales efficiency. By strengthening these relationships, Phibro can ensure that its products are readily available to livestock producers. This strategy could lead to a 5-7% increase in sales volume within the next year.
• Focus on Sustainable Solutions: With increasing consumer awareness of sustainable agriculture practices, Phibro can focus on developing and marketing sustainable animal health and nutrition solutions. This includes products that reduce the environmental impact of livestock production and improve animal welfare. By positioning itself as a leader in sustainable solutions, Phibro can attract environmentally conscious customers and enhance its brand reputation. This focus could contribute to a 3-5% increase in revenue within the next 2 years.

What Opportunities Does PAHC Have?

• Expansion in emerging markets.
• Development of innovative products.
• Strategic acquisitions.
• Increasing demand for sustainable solutions.

What Threats Does PAHC Face?

• Regulatory changes.
• Disease outbreaks.
• Economic downturns.
• Increased competition.

What Are PAHC's Competitive Advantages?

• Diversified product portfolio across animal health and mineral nutrition.
• Global presence in key markets, including the United States, Latin America, and Asia Pacific.
• Established relationships with integrated poultry, swine, and cattle integrators.
• Focus on innovation and development of new products.

What Does PAHC Do?

Phibro Animal Health Corporation, originally known as Philipp Brothers Chemicals, Inc., was renamed in 2003 and incorporated in 2014. Headquartered in Teaneck, New Jersey, the company develops, manufactures, and supplies a comprehensive range of animal health and mineral nutrition products for livestock. Its operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment offers antibacterials, anticoccidials, anthelmintics, anti-bloat treatments, and vaccines. These products cater to various food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The Mineral Nutrition segment provides trace minerals such as zinc, manganese, copper, and iron. The Performance Products segment manufactures specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. Phibro sells its products through local sales offices, targeting integrated poultry, swine, and cattle integrators, as well as commercial animal feed manufacturers, wholesalers, and distributors, with a global presence spanning the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific.

What Products and Services Does PAHC Offer?

• Develops and manufactures animal health products.
• Supplies mineral nutrition products for livestock.
• Offers antibacterials to treat and prevent bacterial diseases in animals.
• Provides anticoccidials to control coccidiosis in poultry and cattle.
• Produces anthelmintics to treat parasitic worm infestations.
• Offers anti-bloat treatment products for cattle.
• Manufactures vaccines to prevent diseases in poultry and swine.
• Creates specialty ingredients for personal care and industrial chemical industries.

How Does PAHC Make Money?

• Develops and manufactures animal health and mineral nutrition products.
• Sells products through local sales offices, commercial animal feed manufacturers, wholesalers, and distributors.
• Operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.

What Industry Does PAHC Operate In?

Phibro Animal Health Corporation operates within the global animal health market, which is driven by the increasing demand for animal protein and the rising awareness of animal health and welfare. The market includes pharmaceuticals, vaccines, feed additives, and diagnostics. Key trends include the growing focus on preventive care and the adoption of precision livestock farming. Phibro competes with companies like OGN: Organon & Co. that offer similar products and services. The industry is subject to regulatory scrutiny and is influenced by factors such as disease outbreaks and trade policies.

Who Are PAHC's Key Customers?

• Integrated poultry, swine, and cattle integrators.
• Commercial animal feed manufacturers.
• Wholesalers and distributors.
• Livestock producers.

Company Profile

Phibro Animal Health Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Teaneck, US. The company is led by CEO Daniel Bendheim. PAHC has traded publicly since 2014.

F-Score 6/9Financial Health

Phibro Animal Health Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.02 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 29%Key Financial Metrics

Return on equity for Phibro Animal Health Corporation stands at 29.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.6%, showing how much profit it generates from its asset base. PAHC trades at a trailing price-to-earnings ratio of 13.13, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.0%, the inverse of the P/E and a quick read on earnings relative to price.

PAHC Valuation & Market Position

With a $1.34B market cap, Phibro Animal Health Corporation sits in the small-cap segment of the market. Relative to its peer group, PAHC's quantitative score of 75/100 is roughly in line with the peer average of 69/100.

FY2026 estForward Outlook

Wall Street analysts project Phibro Animal Health Corporation revenue of about $1.50B for fiscal 2026, with EPS near $3.07. The estimate reflects 4 contributing analysts.

PAHC Financials

PAHC Latest News

PAHC Analyst Consensus

PAHC MoonshotScore

Common Questions About PAHC (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources